Method for treating brain cancer or reducing temozolomide-resistance of brain cancer cells
Provided is a method for treating brain cancer or reducing temozolomide-resistance of brain cancer cells in a subject, comprising administrating to the subject an effective amount of an active ingredient selected from the group consisting of (Z)-butylidenephthalide of formula (I), a pharmaceutically acceptable salt of (Z)-butylidenephthalide, a pharmaceutically acceptable ester of (Z)-butylidenephthalide, and combinations thereof:
1. A method for treating a glioma in a subject, comprising:
administering to the subject (1) an effective amount of the (Z)-butylidenephthalide isomer of formula (I) substantially free from the (E)-butylidenephthalide isomer of formula (I), wherein the (Z)-butylidenephthalide isomer of formula (I) is in the form of the (Z)-butylidenephthalide isomer, a pharmaceutically acceptable salt of the (Z)-butylidenephthalide isomer, a pharmaceutically acceptable ester of the (Z)-butylidenephthalide isomer, or a combination thereof:
and (2) an effective amount of temozolomide, wherein (1) and (2) together provide a combination index less than 1.
2. The method as claimed in claim 1 , wherein the (Z)-butylidenephthalide isomer of formula (I) is in the form of the (Z)-butylidenephthalide isomer.
3. The method as claimed in claim 1 , wherein the glioma is human malignant glioma.
4. The method as claimed in claim 1 , wherein the (Z)-butylidenephthalide isomer of formula (I) is administrated in form of a wafer at a daily dosage of about 30 mg/kg-body weight to about 500 mg/kg-body weight, and temozolomide is administered as a wafer at a daily dosage of about 10 mg/kg-body weight to about 100 mg/kg-body weight.
5. The method as claimed in claim 4 , wherein the (Z)-butylidenephthalide isomer of formula (I) is administered at a daily dosage of about 40 mg/kg-body weight to about 120 mg/kg-body weight, and temozolomide is administrated at a daily dosage of about 40 mg/kg-body weight to about 80 mg/kg-body weight.
6. The method as claimed in claim 1 , wherein the (Z)-butylidenephthalide isomer of formula (I) and temozolomide are administered together, separately, or successively.
7. The method as claimed in claim 1 , wherein the (Z)-butylidenephthalide isomer of formula (I) is administered orally or administered by subcutaneous or intravenous injection and temozolomide is administered orally.